View Post

Biotheranostics’ Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines

In In The News by Barbara Jacoby

From: businesswire.com Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease Breast Cancer Index Endorsed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update Biotheranostics, Inc. announces recommendations for Breast Cancer Index …

View Post

2 Trials, Now Enrolling, Aimed at Improving Breast Cancer Prevention, Diagnosis, and Treatment

In Clinical Trials by Barbara Jacoby

By: Patricia Inacio, PhD From: breastcancer-news.com The University of Hawaiʻi Cancer Center is enrolling participants in two clinical trials to test new ways of preventing and diagnosing breast cancer, as well as improving current treatments. “These trials are very important because breast cancer is a significant issue in Hawaiʻi,” Randall Holcombe, director of the UH Cancer Center said in a press release. “Racial and ethnic minority …

View Post

Breast cancer: Tumor growth fueled by bone marrow cells

In In The News by Barbara Jacoby

By: Ana Sandoiu From: medicalnewstoday.com New research, published in the Journal of Experimental Medicine, reveals a novel mechanism that fuels tumor growth in breast cancer and may have a negative impact on a person’s outlook. However, the findings might also help scientists develop individually tailored treatments that target breast cancer tumors more precisely. Neta Erez, a senior lecturer in the …

View Post

uBiome Announces First Stage of Companion Diagnostic Development in Collaboration with Puma Biotechnology, Inc.

In In The News by Barbara Jacoby

From: prweb.com uBiome, the leader in microbial genomics, today announced the first stage of companion diagnostic development with Puma Biotechnology, Inc. (NASDAQ: PBYI) to investigate the role of the microbiome in adverse events related to neratinib treatment of patients with HER2-positive breast cancer. “This companion diagnostic and clinical trial work is an important part of the future of uBiome,” said …

View Post

Trials Answer Questions About Duration of Treatment in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Angelica Welch From: oncnursingnews.com The optimal duration of treatment for patients with HER2-positive breast cancer has been called into question by recent findings from the NSABP B-52, PERSEPHONE, and APT clinical trials. Priya Rastogi, MD, senior associate medical director, NSABP Medical Affairs, associate professor of Medicine, University of Pittsburgh, shed light on the subject during a presentation she gave …

View Post

“How Connie Got Her Rack Back”

In In The News by Barbara Jacoby

“How Connie Got Her Rack Back” shares the incredible journey of Connie Bramer; a young woman, mom, daughter sister and friend who experienced breast cancer. Connie gives laugh out loud humor to her adventure, along with poignant moments of self-discovery as she blogs her way to good health. From the first page of this book you are laughing out loud …

View Post

PreludeDx Presents Promising Research in Stage 1 Breast Cancer Patients at the 2018 San Antonio Breast Cancer Symposium

In In The News by Barbara Jacoby

From: prnewswire.com Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, announced today its compelling data from research on stage 1 breast cancer patients presented at the 2018 San Antonio Breast Cancer Symposium in San Antonio, TX. The data shows that PreludeDx’s newly-developed assay can stratify risk of local recurrence in stage 1 …

View Post

Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in …